[HTML][HTML] Cardio-oncology: a focus on cardiotoxicity
A Koutsoukis, A Ntalianis, E Repasos… - European Cardiology …, 2018 - ncbi.nlm.nih.gov
Cardio-oncology is a recently developed field in cardiology aimed at significantly reducing
cardiovascular morbidity and mortality and improving quality of life in cancer survivors …
cardiovascular morbidity and mortality and improving quality of life in cancer survivors …
Arterial thrombosis in patients with cancer
M Tuzovic, J Herrmann, C Iliescu… - … treatment options in …, 2018 - Springer
Purpose of review Cancer is a common cause of morbidity and mortality in the USA. While
the association between venous thrombosis and malignancy is well established, arterial …
the association between venous thrombosis and malignancy is well established, arterial …
Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights
PP Zheng, J Li, JM Kros - Medicinal research reviews, 2018 - Wiley Online Library
To date, five cancer treatment modalities have been defined. The three traditional modalities
of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two …
of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two …
Arterial thrombosis and cancer
D Aronson, B Brenner - Thrombosis research, 2018 - Elsevier
Cancer-associated arterial thrombotic events (ATEs) are increasingly recognized in specific
malignancies and in association with the expanding armamentarium of novel …
malignancies and in association with the expanding armamentarium of novel …
Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention
DH Lee, MG Fradley - Current treatment options in cardiovascular …, 2018 - Springer
Purpose of review Multiple myeloma treatment regimens consist of proteasome inhibitors
(bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide …
(bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide …
Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis
TTP Seijkens, E Lutgens - Current opinion in lipidology, 2018 - journals.lww.com
Cardiovascular oncology: exploring the effects of targeted c... : Current Opinion in
Lipidology Cardiovascular oncology: exploring the effects of targeted cancer therapies on …
Lipidology Cardiovascular oncology: exploring the effects of targeted cancer therapies on …
Increased risk of ischemic stroke in multiple myeloma associated with lenalidomide treatment: a case report and review of the literature
E de Celis, MA de Leciñana… - Clinical …, 2018 - journals.lww.com
Increased Risk of Ischemic Stroke in Multiple Myeloma Associ... : Clinical Neuropharmacology
Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide …
Increased Risk of Ischemic Stroke in Multiple Myeloma Associated With Lenalidomide …
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma
EH Yang, C Courtney, V Garg, MG Fradley, GJ Schiller - Cardio-Oncology, 2018 - Springer
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-
free survival in patients when used with standard treatment (lenalidomide and …
free survival in patients when used with standard treatment (lenalidomide and …
[引用][C] Recurrent heart failure with preserved ejection fraction associated with carfilzomib
EH Yang, C Courtney, V Garg - Cardio-Oncology, 4 (1), 2018